The Stock Connect Innovative Drug ETF E Fund (159316) attracted nearly 7 billion in the past year

As of 13:04, the Hang Seng Stock Connect Innovative Drug Index (HSSCID) fell by 3.16%; among the top ten weighted stocks, Innovent Biologics dropped 3.29%, BeiGene dropped 2.51%, CSPC Pharmaceutical Group dropped 3.65%, Akeso dropped 3.03%, China National Pharmaceutical Group dropped 4.02%, Hansoh Pharmaceutical dropped 2.86%, Sansoon Pharmaceutical dropped 2.12%, Kelun-Biotech dropped 4.34%, Zai Lab dropped 1.81%, and Conage-B dropped 3.52%.

The Stock Connect Innovative Drug ETF E Fund (159316) continues to attract capital inflows. As of the previous trading day, the fund had a net inflow of 163 million yuan over the past week, 1.814 billion yuan over the past month, 2.218 billion yuan over the past three months, and 6.997 billion yuan over the past year.

Domestic innovative drugs are entering a period of intensive realization. Recently, relevant authorities approved the listing of four innovative drugs. In the first half of this year, a total of 38 innovative drugs were approved for listing in China, of which 31 were domestic innovative drugs, accounting for more than 80%.

Regarding popular companies, on July 29, CSPC Pharmaceutical Group announced that CRB-701 (SYS6002) has received FDA approval to initiate a registrational clinical trial for the second-line treatment of oropharyngeal squamous cell carcinoma. This product is a next-generation antibody-drug conjugate targeting Nectin-4, showing high expression in various tumors such as urothelial carcinoma, cervical cancer, and head and neck squamous cell carcinoma.

CITIC Securities pointed out that against the backdrop of weak domestic demand, the pharmaceutical sector continues to highlight the high certainty of rigid demand. Coupled with the sustained high growth in domestic biopharmaceutical financing data, pharmaceutical innovation enterprises and global pharmaceutical industry chain enterprises are expected to continue to achieve steady performance growth in the next 3-5 years. Meanwhile, starting from the third quarter this year, the core pipelines of domestic innovative drugs are about to see catalytic releases of key data, and the internationalization value of assets with global potential is expected to be accelerated.

The management fee rate for the Stock Connect Innovative Drug ETF E Fund (159316) is 0.15%, the custody fee rate is 0.05%, and the comprehensive fee rate is 0.2%. The lower fee rates can effectively reduce cost expenditures for investors.

The Stock Connect Innovative Drug ETF E Fund (159316) is currently the only ETF product tracking the Hang Seng Innovative Drug Index in the market, possessing high elasticity and scarcity, helping investors better seize investment opportunities in Hong Kong stock innovative drugs in this round.